col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Publishing House: SCEEMP

38 Results       Page 1

 [1] 
  original article Journal Date Title Authors All Authors
1 [GO] BIOpreparations Prevention Diagnosis Treatment 2024―Oct―02 The problem of SARS-CoV-2 virus resistance to direct-acting antivirals E. L. Gasich, E. N. Krotkova, A. D. Kasko, K. Yu. Bulda, A. G. Krasko, E. A. Dorofeeva, I. A. Karpov
2 [GO] Safety and Risk of Pharmacotherapy 2024―May―03 Analysis of the Consumption of Medicinal Products Associated with a High Risk of Drug-Induced Liver Injury in Patients with COVID-19 V. I. Petrov, A. Yu. Ryazanova, N. S. Tokareva
3 [GO] Safety and Risk of Pharmacotherapy 2024―Feb―01 Quantitative Signal Detection for COVID-19 Medicinal Products Based on Retrospective Analysis of Spontaneous Reports from the Russian Pharmacovigilance Database S. A. Mishinova, A. S. Kolbin, Yu. S. Polushin, E. V. Verbickaya
4 [GO] BIOpreparations Prevention Diagnosis Treatment 2023―Dec―20 Evaluation of humoral immune responses of experimental animals to the recombinant SARS-CoV-2 spike ectodomain with the ISCOM adjuvant V. A. Evseenko, A. V. Zaykovskaya, A. S. Gudymo, O. S. Taranov, S. E. Olkin, A. R. Imatdinov, et al. (+7)
5 [GO] BIOpreparations Prevention Diagnosis Treatment 2023―Oct―04 Comparative safety evaluation of intranasal and intramuscular immunisation with Ad26 and Ad5-vectored vaccines to prevent coronavirus infection E. V. Zuev, O. L. Evdokimova, O. A. Markova, I. A. Korotkevich, T. V. Grigorieva, R. A. Khamitov
6 [GO] BIOpreparations Prevention Diagnosis Treatment 2023―Oct―04 <i>In vitro</i> antiviral activity of a double-stranded RNA sodium salt-based medicinal product against SARS-CoV-2 G. M. Ignatyev, E. Yu. Shustova, E. A. Rogozhina, P. A. Belyi, K. Ya. Zaslavskaya, V. A. Merkulov
7 [GO] Safety and Risk of Pharmacotherapy 2023―Sep―11 A Case of Diabetes Mellitus after COVID-19 Vaccination in a Patient with Impaired Glucose Metabolism I. V. Maiborodin, V. I. Maiborodina, M. G. Klinnikova, E. L. Lushnikova
8 [GO] The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products 2023―Apr―10 The International Pharmacopoeia: Focus, Processes, Response to COVID-19 and Collaboration with other Pharmacopoeias H. Schmidt, J. Sawyer, K. Zribi, R. Van der Werf
9 [GO] BIOpreparations Prevention Diagnosis Treatment 2022―Dec―30 Preclinical studies of antiviral activity of the RPH-137 fusion protein and molnupiravir against COVID-19 E. V. Shipaeva, O. V. Filon, A. V. Zintchenko, G. A. Shipunov, A. A. Dmitrieva, M. S. Lemak, et al. (+9)
10 [GO] BIOpreparations Prevention Diagnosis Treatment 2022―Dec―30 Levilimab clinical efficacy for interleukin-6 receptor inhibition in COVID-19 and its potential for treating cytokine release syndrome of other aetiologies N. V. Lomakin, B. A. Bakirov, G. H. Musaev, V. V. Popov, E. A. Smolyarchuk, Yu. N. Linkova, et al. (+6)
11 [GO] Safety and Risk of Pharmacotherapy 2022―Dec―30 Structure of Adverse Events Following Immunisation against Coronavirus Infection (COVID-19) in the Kyrgyz Republic A. A. Zurdinova, Zh. O. Zhumagulova, A. T. Sharaeva, N. Sultanalieva
12 [GO] BIOpreparations Prevention Diagnosis Treatment 2022―Dec―30 Environmental, biological and social factors contributing to new rises in COVID-19 morbidity in Russia T. E. Sizikova, V. N. Lebedev, S. V. Borisevich
13 [GO] Safety and Risk of Pharmacotherapy 2022―Dec―30 Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review A. V. Kryukov, A. S. Zhiryakova, Yu. V. Shevchuk, A. V. Matveev, V. I. Vechorko, O. V. Averkov, et al. (+6)
14 [GO] BIOpreparations Prevention Diagnosis Treatment 2022―Dec―30 Aspects and issues of marketing authorisation and use of medicinal products for COVID-19 prevention during the pandemic A. A. Soldatov, D. V. Gorenkov, V. A. Merkulov, V. P. Bondarev
15 [GO] Safety and Risk of Pharmacotherapy 2022―Dec―30 Is the Combination Nirmatrelvir Plus Ritonavir Effective for Treating or Preventing COVID-19? Article Editorial
16 [GO] Safety and Risk of Pharmacotherapy 2022―Dec―30 Experience of Using Remdesivir in Patients with Novel Coronavirus Infection V. I. Petrov, A. Yu. Ryazanova, N. S. Privaltseva, D. A. Nekrasov
17 [GO] BIOpreparations Prevention Diagnosis Treatment 2022―Dec―30 The use of quantitative enzyme-linked immunosorbent assay for the determination of S-antigen concentration in whole-virion inactivated adsorbed coronavirus vaccines A. S. Oksanich, A. G. Krasko, T. G. Samartseva, E. L. Gasich, G. M. Ignatyev
18 [GO] BIOpreparations Prevention Diagnosis Treatment 2022―Dec―30 Selection of a SARS-CoV-2 antibody quantification method and development of an antibody reference standard for ELISA to test immunoglobulin preparations T. I. Smolyanova, A. M. Nikolaeva, T. V. Vyaznikova, A. V. Ivanov, O. V. Belyakova, E. I. Sakanyan
19 [GO] BIOpreparations Prevention Diagnosis Treatment 2022―Dec―30 An experience of scaling and intensifying the industrial production of the Gam-COVID-Vac vector adenovirus vaccine in the limiting conditions of the pandemic A. N. Morozov, I. R. Yakhin, N. V. Stratonova, M. V. Kutskir, D. A. Poteryaev, R. A. Khamitov
20 [GO] Safety and Risk of Pharmacotherapy 2022―Dec―30 Vladimir Chulanov: “Our experience with overcoming the pandemic will help us effectively address future threats” Article Editorial
21 [GO] Safety and Risk of Pharmacotherapy 2022―Oct―31 Safety of COVID-19 Vaccines B. K. Romanov
22 [GO] Safety and Risk of Pharmacotherapy 2022―Oct―06 Approaches to Assessing the Safety of Medicines during the COVID-19 Pandemic Using the Example of Azithromycin Yu. M. Gomon, A. R. Kasimova, A. S. Kolbin, V. V. Strizheletsky, I. G. Ivanov, S. O. Mazurenko
23 [GO] Safety and Risk of Pharmacotherapy 2022―Jul―19 Evaluation of the Rationality of Antibiotic Therapy of Nosocomial Infections in Resuscitation and Intensive Care Patients with COVID-19: a Retrospective Analysis K. I. Karnoukh, N. B. Lazareva
24 [GO] Safety and Risk of Pharmacotherapy 2022―Jul―04 Antibiotics for the treatment of COVID-19 Article Editorial
25 [GO] Safety and Risk of Pharmacotherapy 2022―Apr―11 Ivermectin: Evaluation of Efficacy and Safety in COVID-19 E. V. Shubnikova, N. A. Susekova, T. M. Bukatina, M. S. Galenko, A. A. Druzhinina
26 [GO] Safety and Risk of Pharmacotherapy 2022―Apr―11 Changes in Post-COVID Syndrome Manifestations and Bulbar Conjunctival Angioscopy Results in a Patient Undergoing Treatment after Mild COVID-19 V. V. Arkhipov, T. S. Kheilo, E. G. Gladysheva, Yu. A. Danilogorskaya, M. R. Dzhavatkhanova, S. V. Snytko, et al. (+2)
27 [GO] BIOpreparations Prevention Diagnosis Treatment 2021―Dec―22 Comparative analysis of existing platforms for the development of vaccines against dangerous and extremely dangerous viral infections with pandemic potential G. G. Onishchenko, T. E. Sizikova, V. N. Lebedev, S. V. Borisevich
28 [GO] Safety and Risk of Pharmacotherapy 2021―Dec―21 Experience in Using Antiviral Agents for the Treatment of Novel Coronavirus Infection (COVID-19) in Kyrgyzstan A. A. Zurdinova, A. Z. Kutmanova
29 [GO] BIOpreparations Prevention Diagnosis Treatment 2021―Oct―04 Assessment of T-cell immunity to SARS-CoV-2 in COVID-19 convalescents and vaccinated subjects, using TigraTest® SARS-CoV-2 ELISPOT kit D. A. Poteryaev, S. G. Abbasova, P. E. Ignatyeva, O. M. Strizhakova, S. V. Kolesnik, R. A. Khamitov
30 [GO] BIOpreparations Prevention Diagnosis Treatment 2021―Oct―04 Comparative characteristics of COVID-19 vaccines used for mass immunisation G. G. Onishchenko, T. E. Sizikova, V. N. Lebedev, S. V. Borisevich
31 [GO] The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products 2021―Mar―10 Planning Bioequivalence Studies in the Context of the COVID-19 Pandemic D. P. Romodanovsky, A. L. Khokhlov, D. V. Goryachev
32 [GO] BIOpreparations Prevention Diagnosis Treatment 2020―Dec―15 Analysis of Promising Approaches to COVID-19 Vaccine Development G. G. Onishchenko, T. E. Sizikova, V. N. Lebedev, S. V. Borisevich
33 [GO] BIOpreparations Prevention Diagnosis Treatment 2020―Dec―15 Russian and International Regulatory Recommendations for the Development and Marketing Authorisation of COVID-19 Vaccines in the Context of the Pandemic A. A. Soldatov, Zh. I. Avdeeva, V. P. Bondarev, V. A. Merkulov, V. D. Mosyagin, V. B. Ivanov, et al. (+2)
34 [GO] BIOpreparations Prevention Diagnosis Treatment 2020―Sep―18 Prospects for Using the ELISPOT Technological Platform as Part of Anti-Epidemic Measures Against the New Coronavirus Infection COVID-19 D. A. Poteryaev, R. A. Khamitov, G. A. Efimov, A. M. Shuster
35 [GO] The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products 2020―Sep―18 Safety of Hydroxychloroquine, Favipiravir, and the Combination of Lopinavir and Ritonavir in the Treatment of the “First Wave” of the New Coronavirus Infection COVID-19 B. K. Romanov
36 [GO] Safety and Risk of Pharmacotherapy 2020―Sep―18 Safety of Remdesivir and Tocilizumab in COVID-19 Treatment Article Editorial
37 [GO] Safety and Risk of Pharmacotherapy 2020―Mar―28 Coronavirus disease COVID-2019 B. K. Romanov
38 [GO] BIOpreparations Prevention Diagnosis Treatment 2020―Mar―26 An Outbreak of a New Infectious Disease COVID-19: β-coronaviruses as a Threat to Global Healthcare D. V. Gorenkov, L. M. Khantimirova, V. A. Shevtsov, A. V. Rukavishnikov, V. A. Merkulov, Yu. V. Olefir
 [1] 

38 Results       Page 1



[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.005 sec